Phase 3 N=40 Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Time to 99% Inhibition of Serum Thromboxane (TxB2) — 12.36; 16.65; 48.64 Hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=57 Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Time to 99% Inhibition of Serum Thromboxane — 26.71; 64.57 hours
Phase 4 N=70 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
Cardiovascular Diseases · Metabolic Syndrome X · Atherosclerosis
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL
Phase 4 N=302 Clopidogrel and Aspirin Interaction Study-2
Drug Action Increased
Primary: Blood Concentration of the Active Metabolite of Clopidogrel — 14.45; 13.80 ng/ml — p=0.66
Phase 4 N=110 Postpartum ASA and NT-proBNP
Blood Pressure
Primary: NT-proBNP Levels at 4-6 Weeks Postpartum — 36.5; 39.5 pg/mL — p=0.49
Phase 4 N=37 Aspirin Dose and Atherosclerosis in Patients With Heart Disease
Cardiovascular Diseases · Atherosclerosis · Myocardial Infarction
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL
Phase 1 N=102 Naproxen Sodium/ASA Platelet Study
Hematology
Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage
N/A N=9 Biosynthesis of PGD2 in Vivo
Hyperlipidemia
Primary: Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo — 95; 43 Percentage change…
N/A N=9 Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers
Aspirin Blood Level · Proton Pump Inhiditor Treatment
Primary: Aspirin Level in Blood (Area Under the Curve) — 49.4; 50.7; 8.7; 6.5 mg*hour/mL
Phase 4 N=36 Aspirin Dosing in Diabetic Patients
Type 2 Diabetes Mellitus · Coronary Artery Disease
Primary: Collagen Induced Aggregation — 32 percentage of platelet aggregation
N/A N=36 Comparative Effects of Aspirin and NHP-544C
Healthy
Primary: Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose — 0.181; 0.255 ng/mg creatinine
Phase 4 N=72 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Acute Coronary Syndrome
Primary: Assess Inflammatory Response to Intravenous Endotoxin — 167.53; 111.05; 254.92; 128.73 pg/ml
N/A N=4 Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects
Healthy
Primary: Change in Exhaled Inflammatory Mediator Levels — 1.42 pg/mL
N/A N=15,076 Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term
Atherosclerotic Cardiovascular Disease
Primary: Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI…
N/A N=1,228 The Effects of Aspirin in Gestation and Reproduction
Birth · Spontaneous Abortion
Primary: Live Birth — 309; 286 livebirths — p=0.0984
Early Phase 1 N=92 Aspirin Resistance in Coronary Artery Disease
Coronary Artery Disease
Primary: Change in Serum Thromboxane B2 — 5.02; 2.78 ng/mL — p=0.005
N/A N=64 Validation of an Assay to Measure Cyclooxygenase-1 Activity
Healthy
Primary: A Reference Range in Normal Volunteers Taking a Routine Clinical Dose of Aspirin (81mg Daily) for 2 Weeks — 13 ng/ml
Phase 4 N=36 Aspirin Responsiveness in Women at Risk for Cardiac Events
Heart Disease
Primary: Number of Women Aspirin Resistant — 3 participants
N/A N=55 Mechanisms of Action of Acetaminophen
Myocardial Infarction · Arthritis
Primary: Percent Change in Serum Thromboxane B2 — 97.0; 97.4; 98.3; 96.7 Percent inhibition of baseline — p=>0.05
N/A N=15 Aspirin Responsiveness in Women With Coronary Artery Disease
CAD
Primary: Women With Known CAD Who Are Hyporesponsive to Low Dose (81 mg) Aspirin — 0 participants
Phase 4 N=46 WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
Coronary Syndrome
Primary: Bleeding Time Difference — 0; 75; -15 s
Phase 3 N=37 Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
Multiple Sclerosis
Primary: Time-to-exhaustion — 551.7; 331.6; 578.2 seconds
N/A N=132 Genotypic and Phenotypic Correlates of Resistance to Aspirin
Platelet Dysfunction Due to Aspirin
Primary: Whole Blood Coagulation — 453.8 Aspirin response units (ARU)
Phase 3 N=400 Low Doses of Aspirin in the Prevention of Preeclampsia
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
Phase 4 N=244 Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
Cerebral Infarction
Primary: Aspirin Resistance (ARU ≥ 550) — 9; 11 participants — p=0.654
Phase 2 N=54 Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
Lung Carcinoma · Tobacco Use Disorder
Primary: Changes in Smoking-related Gene Expression Signature Score in Nasal Epithelium — -1.11; 1.39 gene expression signature score — p=0.04
Phase 2 N=121 Modulation of Immune Activation by Aspirin
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70
Phase 3 N=70 Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
Peripheral Artery Disease · Type 2 Diabetes
Primary: Mean Change in Low Shear Blood Viscosity — 1.045; -1.793; -1.759 5 s^-1 cPs
Phase 2 N=400 LIPS-A: Lung Injury Prevention Study With Aspirin
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
Phase 2 N=27 The Effects of Omega-3 Fatty Acids on Aspirin Resistance
Increased Drug Resistance
Primary: the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment — 0.0; 10.9; -6.5; 30.5 seconds — p=0.00